Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

AstraZeneca’s (AZN - Analyst Report) global biologics research and development arm, MedImmune, has acquired privately-held biotech company, Spirogen. Spirogen focuses on developing oncology related technology. As per the terms of the agreement, AstraZeneca acquired all shares of Spirogen for an initial consideration of $200 million and milestone payments of up to $240 million depending on attainment of predetermined targets.

AstraZeneca will also make a $20 million equity investment in Swiss-based oncology drug development company, ADC Therapeutics. As per the terms of the agreement, the companies will co-develop two of ADC Therapeutics’ candidates in preclinical development.

We remind investors that AstraZeneca acquired privately-held U.S. based company, Amplimmune, in Oct 2013. The deals are in line with AstraZeneca’s strategy of boosting its pipeline by acquiring candidates.

Generic competition has been adversely impacting AstraZeneca’s revenues over the past few quarters. This has put significant pressure on the company.

In a bid to add late-stage candidates to its pipeline, AstraZeneca entered into a number of acquisition deals (Pearl Therapeutics and Omthera Pharmaceuticals) in the last few months and agreements with companies such as FibroGen, Inc.

Meanwhile, AstraZeneca has entered into an agreement with Janssen Pharmaceutical K.K., a subsidiary of Johnson & Johnson (JNJ - Analyst Report), to co-promote abiraterone acetate for prostate cancer in Japan. The drug is currently under regulatory review in Japan.

AstraZeneca, a large-cap pharma company, presently carries a Zacks Rank #3 (Hold). Other large-cap pharma stocks such as Roche (RHHBY - Analyst Report) and Bayer (BAYRY - Analyst Report) currently appear more attractive. While Roche carries a Zacks Rank #1(Strong Buy), Bayer carries a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%